Fate Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fate Therapeutics, Inc. on October 14, 2025, covering events occurring on October 10, 2025, and October 13, 2025. The filing addresses significant changes to the Company's Board of Directors and executive leadership, specifically the resignation of two directors and the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- Board Resignations: John D. Mendlein, Ph.D., J.D., and Neelufar Mozaffarian, M.D., Ph.D., FACR, resigned from the Board effective October 13, 2025. Dr. Mozaffarian also resigned from the Nominating and Corporate Governance Committee and the Science and Technology Committee.
- Board Size Reduction: Following the resignations, the Board size was reduced from ten (10) to eight (8) directors.
- Executive Appointment: Kamal Adawi, M.S., M.B.A., was appointed as Chief Financial Officer, effective October 20, 2025. He also assumes the roles of principal financial officer and principal accounting officer, replacing Bahram Valamehr in those specific capacities.
- Leadership Continuity: Bahram Valamehr continues to serve as President, Chief Executive Officer, principal executive officer, and a Director.
Compensation and Outlook
In connection with his appointment, Mr. Adawi received an at-will employment offer with the following compensation terms:
- Base Salary: $495,000 annually.
- Performance Bonus: Target amount equal to 40% of the annual base salary.
- Stock Options: 375,000 shares under the Inducement Equity Plan. Vesting schedule: 25% on the first anniversary of the appointment date, with the balance vesting in equal monthly installments over the subsequent 36 months.
- Restricted Stock Units (RSUs): 75,000 shares. Vesting schedule: 25% in equal annual installments over four years starting November 1, 2025.
- Benefits: Eligible for the Company's Severance and Change in Control Policy, health benefits, 401(k), and vacation plans.
The resignations of the directors were voluntary and not the result of any disagreement with the Company regarding operations, practices, or policies. The filing does not contain specific guidance, risk factors, or contingencies beyond the standard disclosures regarding the new executive's employment terms.
Investor Verification Checklist
- Verify the effective date of the Board size reduction (October 13, 2025) and the composition of the remaining eight directors.
- Review the full text of the Offer Letter (Exhibit 10.1) for detailed vesting acceleration clauses and severance terms.
- Confirm the transition timeline for Mr. Adawi's assumption of duties as principal financial and accounting officers on October 20, 2025.
- Assess the impact of the reduced Board size on committee structures, particularly the Science and Technology Committee following Dr. Mozaffarian's departure.